Ironwood wraps up global rights to Bionomics' promising anxiety candidate
This article was originally published in Scrip
Executive Summary
Bionomics has struck the first out-licensing deal for its clinical-stage pipeline, tying up with the US firm Ironwood Pharmaceuticals for the worldwide development and commercialisation of BNC210 and related compounds, initially for the treatment of anxiety.